Advisor Group’s Apellis Pharmaceuticals APLS Stock Holding History

Advisor Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$3K	Hold	100	–	–	﹤0.01%	4819
2019 Q3	$2K	Buy	+100	New	+$2.75K	﹤0.01%	4941

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Advisor Group's APLS Position: Q4 2019 in Review

Advisor Group held its Apellis Pharmaceuticals (APLS) position steady in Q4 2019 at 100 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4819.

Advisor Group first reported a position in APLS in Q3 2019 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

Advisor Group held 100 shares of Apellis Pharmaceuticals worth $3K as of Q4 2019.
Advisor Group left its Apellis Pharmaceuticals share count unchanged in Q4 2019.
Apellis Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4819 holding.
Advisor Group first reported a position in Apellis Pharmaceuticals in Q3 2019 and has held it in 2 quarters since.
133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.